At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,555 enrolled
Drug / intervention
Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo Israel Pharmaceuticals, Ltd., Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to a Comparator Clindamycin / Benzoyl Peroxide Topical Gel, and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
In Brief
A Phase 3 clinical trial evaluating Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo), Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin), and 1 other intervention for Acne Vulgaris. Completed, enrolled 1,555 participants.
Detailed Summary
The purpose of this study is to compare the efficacy and safety profiles of Perrigo Israel Pharmaceuticals, Ltd. Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel and Benzaclin® Topical Gel (Clindamycin- Benzoyl Peroxide Gel).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedJun 2010
Primary CompletionOct 2010
TodayJul 2026
First PostedJun 7, 2010
Enrollment StartOct 1, 2009
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.1 years ago
Interventions
Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)drug
Applied to the entire face twice daily for 10 weeks
Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)drug
Applied to the entire face twice daily for 10 weeks
Placebodrug
Placebo